The impact of monoclonal antibodies in preventing antimicrobial resistance (AMR)

Abstract

Monoclonal antibodies (mAbs) have transformed modern medicine through precision targeting and therapeutic efficacy. This summary summarises the development, applications, and comparative characteristics of mAbs in the context of antiviral medicines and antibiotic treatment durations. Monoclonal antibodies are designed to target specific antigens with great affinity and specificity, making them important for diagnostics and treatments. Anti-virulence mAbs, a type of mAb, target pathogen virulence factors rather than pathogens themselves, providing a promising technique for combating infectious diseases while limiting resistance development. When comparing the duration of antibiotic medication versus mAb treatment, mAbs frequently provide a shorter and more tailored therapeutic regimen. This can lead to better patient outcomes, less resistance, and a lower risk of side effects associated with long-term antibiotic usage. Antigen selection, hybridoma creation, antibody synthesis, purification, and characterization are all steps in the mAb development process, with advances like recombinant DNA technology improving efficiency and scalability.